Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments.

Protein Eng Des Sel

Christian Doppler Laboratory for Innovative Immunotherapeutics, Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU), Vienna, Muthgasse 18, 1190 Vienna, Austria.

Published: September 2017

Fc fragment with antigen-binding (Fcab) is a novel construct which can be selected to recognize specifically a wide variety of target proteins. We describe the selection and affinity maturation of Fcab clones targeting VEGF, an important pro-angiogenesis factor. To investigate the extent of engineering permissible to Fcabs we applied targeted mutagenesis to all three C-terminal loop structures and the C-terminus of the CH3 domain to isolate high-affinity binders by directed evolution and yeast display. The matured clone, CT6, binds to VEGF with low nanomolar affinity and inhibits VEGF-stimulated proliferation of human umbilical vein endothelial cells in vitro. Molecular dynamics simulations were performed to address flexibility of the molecular structure of CT6 and to approximate a structural ensemble in aqueous solution. Significantly higher RMSF levels of CT6 in comparison to wild-type Fc were limited to the elongated CD-loop in the CH3 domain, while the overall structural integrity was retained. This allowed the Fcab to replace the Fc portion of a mAb, in which both the CH3 and Fab are capable of antigen engagement: a construct called mAb2 was assembled with CT6 and the Fab of bevacizumab. This bispecific molecule showed more potent antagonistic activity than bevacizumab in vitro. Further evaluation for the potential of the CT6 Fcab in targeted therapy is warranted due to the possibility of being combined with other therapeutically meaningful targets.

Download full-text PDF

Source
http://dx.doi.org/10.1093/protein/gzx042DOI Listing

Publication Analysis

Top Keywords

ch3 domain
8
ct6
5
designing fcabs
4
fcabs well-expressed
4
well-expressed stable
4
stable high
4
high affinity
4
affinity antigen-binding
4
antigen-binding fragments
4
fragments fragment
4

Similar Publications

MFSD6 is an entry receptor for respiratory enterovirus D68.

Cell Host Microbe

December 2024

Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, China; Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, Jilin 130021, China; Institute of Translational Medicine, Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital of Jilin University, Changchun, Jilin 130021, China. Electronic address:

Enterovirus D68 (EV-D68) is a leading non-polio enterovirus that causes severe respiratory diseases and poliomyelitis-like illness in children. Viral entry represents a potential multifaceted target for antiviral intervention; however, there are no approved inhibitors to block EV-D68. Here, we identify the functionally undescribed membrane protein major facilitator superfamily-domain-containing protein 6 (MFSD6) as an EV-D68 entry factor amenable to therapeutic intervention.

View Article and Find Full Text PDF

FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology.

Cell Metab

December 2024

Department of Pharmacology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China. Electronic address:

Immunoglobulin G (IgG) is traditionally recognized as a plasma protein that neutralizes antigens for immune defense. However, our research demonstrates that IgG predominantly accumulates in adipose tissue during obesity development, triggering insulin resistance and macrophage infiltration. This accumulation is governed by neonatal Fc receptor (FcRn)-dependent recycling, orchestrated in adipose progenitor cells and macrophages during the early and late stages of diet-induced obesity (DIO), respectively.

View Article and Find Full Text PDF

Post expression from the host cells, biotherapeutics undergo downstream processing steps before final formulation. Mass spectrometry and biophysical characterization methods are valuable for examining conformational and stoichiometric changes at these stages, although typically not used in biomanufacturing, where stability is assessed via bulk property studies. Here we apply hybrid MS methods to understand how solution condition changes impact the structural integrity of a biopharmaceutical across the processing pipeline.

View Article and Find Full Text PDF

Using IMGT unique numbering for IG allotypes and Fc-engineered variants of effector properties and half-life of therapeutic antibodies.

Immunol Rev

November 2024

IMGT®, the international ImMunoGeneTics information system® (IMGT), Laboratoire d'ImmunoGénétique Moléculaire (LIGM), Institut de Génétique Humaine (IGH), UMR 9002 Centre National de la Recherche Scientifique (CNRS), Université de Montpellier (UM), Montpellier Cedex 5, France.

Article Synopsis
  • Therapeutic monoclonal antibodies (mAbs) are primarily of the IgG1, IgG2, and IgG4 classes, and their effectiveness can be enhanced by modifying heavy chains for improved immune responses and longer half-life.
  • Allotypes and Fc-engineered variants of these antibodies are classified using a specific nomenclature (IMGT/HGNC) that designates their species and modifications based on amino acid variations.
  • In total, 126 variants are identified, each characterized by specific motifs that relate to their functions, such as effector capabilities and half-life, aiding in their classification and therapeutic applications.
View Article and Find Full Text PDF

Advances in antibody engineering are being directed at the development of next generation immunotherapeutics with improved potency. Hexamerisation of IgG is a normal physiological aspect of IgG biology and recently described mutations that facilitate this process have a substantial impact upon monoclonal antibody behavior resulting in the elicitation of dramatically enhanced complement-dependent cytotoxicity, Fc receptor function, and enhanced antigen binding effects, such as targeted receptor agonism or microbe neutralization. Whereas the discovery of IgG hexamerisation enhancing mutations has largely focused on residues with exposure at the surface of the Fc-Fc and CH2-CH3 interfaces, our unique approach is the engineering of the mostly buried residue H429 in the CH3 domain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!